Alluvi, previously BI 4744, represents a significant advance in weight control therapy. This dual stimulator targeting both GLP-1 and glucose-dependent insulinotropic polypeptide receptors demonstrates compelling https://alluvi-peptides825755.wikiparticularization.com/user